Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Capital Leases (2022 - 2025)

aTYR PHARMA (ATYR) has disclosed Capital Leases for 4 consecutive years, with $259000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Leases fell 70.8% year-over-year to $259000.0, compared with a TTM value of $259000.0 through Dec 2025, down 70.8%, and an annual FY2025 reading of $259000.0, down 70.8% over the prior year.
  • Capital Leases was $259000.0 for Q4 2025 at aTYR PHARMA, down from $398000.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $1.6 million in Q1 2023 and bottomed at $259000.0 in Q4 2025.
  • Average Capital Leases over 4 years is $951000.0, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Capital Leases surged 411.74% in 2023, then crashed 70.8% in 2025.
  • Year by year, Capital Leases stood at $1.0 million in 2022, then soared by 41.81% to $1.4 million in 2023, then tumbled by 37.89% to $887000.0 in 2024, then plummeted by 70.8% to $259000.0 in 2025.
  • Business Quant data shows Capital Leases for ATYR at $259000.0 in Q4 2025, $398000.0 in Q3 2025, and $602000.0 in Q2 2025.